The estimated Net Worth of Marc Belsky is at least $1.6 Milion dollars as of 4 February 2020. Mr. Belsky owns over 15,384 units of Kezar Life Sciences Inc stock worth over $8,923 and over the last 10 years he sold KZR stock worth over $0. In addition, he makes $1,595,870 as Chief Financial Officer a Secretary at Kezar Life Sciences Inc.
Marc has made over 8 trades of the Kezar Life Sciences Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 15,384 units of KZR stock worth $39,998 on 4 February 2020.
The largest trade he's ever made was exercising 34,102 units of Kezar Life Sciences Inc stock on 22 April 2016 worth over $319,536. On average, Marc trades about 2,873 units every 47 days since 2014. As of 4 February 2020 he still owns at least 15,384 units of Kezar Life Sciences Inc stock.
You can see the complete history of Mr. Belsky stock trades at the bottom of the page.
Marc L. Belsky serves as Chief Financial Officer, Secretary of the Company. Prior to joining us, from October 2009 to April 2018, Mr. Belsky held several roles at Five Prime Therapeutics, Inc., a publicly held biopharmaceutical company, including most recently as Senior Vice President and Chief Financial Officer. Prior to that, Mr. Belsky served in various roles at Cell Genesys, Inc., a biotechnology company acquired by BioSante Pharmaceuticals, Inc., Active Aero Group, Inc., DataWave Systems Inc. and Michigan National Corporation, a holding company for Michigan National Bank, which was acquired by BANA Holding Corporation. Mr. Belsky started his career as an auditor with Coopers & Lybrand. Mr. Belsky received a B.S. degree in accounting from Wayne State University and an M.B.A. degree from the University of Michigan. He is a certified public accountant.
As the Chief Financial Officer a Secretary of Kezar Life Sciences Inc, the total compensation of Marc Belsky at Kezar Life Sciences Inc is $1,595,870. There are 2 executives at Kezar Life Sciences Inc getting paid more, with John Fowler having the highest compensation of $3,532,020.
Marc Belsky is 64, he's been the Chief Financial Officer a Secretary of Kezar Life Sciences Inc since 2018. There are 2 older and 11 younger executives at Kezar Life Sciences Inc. The oldest executive at Kezar Life Sciences Inc is Franklin Berger, 70, who is the Independent Director.
Marc's mailing address filed with the SEC is C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 6 years, insiders at Kezar Life Sciences Inc have traded over $3,836,099 worth of Kezar Life Sciences Inc stock and bought 6,372,267 units worth $30,891,130 . The most active insiders traders include Venture Investments Ltd Mor..., Asset Management, Lp Chen B... a Franklin M Berger. On average, Kezar Life Sciences Inc executives and independent directors trade stock every 49 days with the average trade being worth of $91,954. The most recent stock trade was executed by Mark C. Schiller on 2 July 2024, trading 6,688 units of KZR stock currently worth $3,879.
kezar life sciences, inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the united states. the company's lead product candidate is kzr-616, a selective immunoproteasome inhibitor that is in phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. its preclinical products include kzr-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and kzr-tbd for the treatment of oncology and autoimmunity. the company was founded in 2015 and is headquartered in south san francisco, california.
Kezar Life Sciences Inc executives and other stock owners filed with the SEC include: